Product Search
Our History
  • Became the holding company of VCP Pharmaceutical Joint Stock Company.
  • Set up the joint venture company Sinopharm-FTZ Logistics Co., Ltd. with Beijing Tianzhu Free Trade Zone development and management center.
  • China Sinopharm International Corporation was formed on the basis of SINOPHARM FOREIGN TRADE together with CNSC and CTPFTC.
  • Set up China National Pharmaceutical Group (Vietnam) Pharmaceutical Co., Ltd. in Ha Noi.
  • Set up the first and the only GMP-WHO/GSP/GLP certified manufacturing plant of power-injection in Vietnam, i.e. VCP Pharmaceutical Joint Stock Company.
  • Awarded "Credible Import & Export Company" (one of 155) by China Customs.
  • Established HM Science, Inc., a Joint Venture with China National Group of Traditional & Herbal Medicines and Kanebo Trinity Holdings Group (presently, Kracie Holdings Ltd.), Japan.
  • ISO9001:2000 certified for overseas labor cooperation and project contacting, by China Quality Certification Center.
  • Became an ISO 9001:2000 certified company, audited and certified by SGS.
  • Received the first GSP (Good Supply Practice) certificate in Beijing from Beijing SDA (State Drug Administration).
  • Became one of the 11 AA Companies approved by Beijing Customs (Top Category).
  • Started its domestic marketing business of import drugs, and contracting business of overseas pharmaceutical engineering projects.
  • Set up a public bonded warehouse approved by Beijing Customs, the first and the only bonded warehouse for pharmaceuticals in Beijing.
  • Established the first Sino-Vietnamese pharmaceutical Joint Venture, Vietnam-China Pharmaceutical Co. Ltd. (presently, Vietnam-China Pharmaceutical Joint Stock Company, VCP) in Hanoi, Vietnam, co-invested with Central Pharmaceutical Factory No. I, Vietnam. VCP is the first WHO-GMP and GLP/GSP approved manufacturer of powder injections in Vietnam.
  • Formed China National Pharmaceutical Group Corporation (SINOPHARM Group), with three other SPAC's companies (China National Pharmaceutical Industry Corporation, China National Medicine Corporation and China National Medical Equipment Industry Corporation).
  • Established a GMP production line of Betalactam Antibiotics for Injection in Hanoi, Vietnam, co-invested with Zhangjiakou Pharmaceutical Corp., China and Central Pharmaceutical Factory No. I, Vietnam.
  • Chosen by the State Council of China as one of 100 pilot companies to carry out the Modern Corporate System Reform. Afterwards, SINOPHARM was separated from SPAC and became an independent state-owned company who makes its own management decisions and takes full responsibility for its profits and losses.
  • Set up SINOPHARM Foreign Trade (Hong Kong) Ltd., a subsidiary based in Hong Kong, and started to explore Hong Kong market.
  • Set up Sales Company (presently, Domestic Distribution Company) a subsidiary, in Beijing and started its domestic distribution business of import drugs.
  • Set up an office in Hanoi, Vietnam and started to explore the market of Southeast Asia.
  • Started to use SINOPHARM as its abbreviation.
  • Listed in the ranking of Top 500 Chinese Companies in terms of import & export volume, issued by MOFTEC, and has kept in the list ever since.
  • Changed the company's name to China National Pharmaceutical Foreign Trade Corporation, and Started import and export business of APIs and pharmaceutical technology import.
  • Established GlaxoSmithKline Pharmaceuticals (Chongqing) Ltd., a Joint Venture with GlaxoSmithKline plc., UK.
  • Established Qingdao Huazhong Pharmaceutical Ltd., a Joint Venture with Kanebo Trinity Holdings Group (presently, Kracie Holdings Ltd.).
  • Established Xian-Janssen Pharmaceutical Ltd., a Joint Venture with Janssen Pharmaceutica NV (member of Johnson & Johnson).
  • Established Sino-American Capsugel® (Suzhou) Ltd. (presently, Suzhou Capsugel Limited, SCL), a Joint Venture with Warner-Lambert Company (presently, Capsugel Division of Pfizer Inc.).
  • Established Sino-American Shanghai Squibb Pharmaceutical Ltd. (SASS), a Joint Venture with Bristol-Myers Squibb Company.
  • Established Sino-Swed Pharmaceutical Corporation Ltd. (SSPC), a Joint Venture with Pharmacia & Upjohn, Inc. (whose shares were transferred to Fresenius Kabi, Germany in 1999).
  • Established the first Sino-foreign pharmaceutical Joint Venture in China, China Otsuka Pharmaceutical Co., Ltd. (COP), co-invested with Otsuka Pharmaceutical Co., Ltd., Japan.
  • Transferred new process technology of Vitamin C two-phase fermentation to Roche, on behalf of Chinese pharmaceutical industry.
  • The company was founded with the name of CPIC (China Pharmaceutical Corporation for International Economic and Technological Cooperation), directly under State Pharmaceutical Administration Committee (SPAC; presently, SFDA). The company was a window to foreign countries on behalf of SPAC. It worked to carry out economic and technological cooperation, introduce new technology for technical upgrade, and set up joint ventures in China on behalf of Chinese pharmaceutical authorities and industry with foreign multinationals.